dc.creator | Zlocowski, Natacha | |
dc.creator | Grupe, Verónica Maria | |
dc.creator | Garay, Yohana Camila | |
dc.creator | Nores, Gustavo Alejandro | |
dc.creator | Lardone, Ricardo Dante | |
dc.creator | Irazoqui, Fernando Jose | |
dc.date.accessioned | 2021-03-24T15:04:14Z | |
dc.date.accessioned | 2022-10-14T22:08:47Z | |
dc.date.available | 2021-03-24T15:04:14Z | |
dc.date.available | 2022-10-14T22:08:47Z | |
dc.date.created | 2021-03-24T15:04:14Z | |
dc.date.issued | 2019-12 | |
dc.identifier | Zlocowski, Natacha; Grupe, Verónica Maria; Garay, Yohana Camila; Nores, Gustavo Alejandro; Lardone, Ricardo Dante; et al.; Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues; Nature Publishing Group; Scientific Reports; 9; 1; 12-2019; 1-11 | |
dc.identifier | http://hdl.handle.net/11336/128870 | |
dc.identifier | 2045-2322 | |
dc.identifier | CONICET Digital | |
dc.identifier | CONICET | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4312227 | |
dc.description.abstract | Described in several epithelial cancer cells, Tn- (GalNAcα1-O-Ser/Thr) and T- (Galβ3GalNAcα1-O-Ser/Thr) antigens are examples of tumor-associated antigens. Increased expression of Tn- and T-antigens is associated with tumor invasion and metastasis, and patients with high concentration of anti-Tn and anti-T antibodies have a more benign evolution of pathology. Asialofetuin (ASF) and ovine submaxillary mucin (OSM) are two glycoproteins that expose T- and Tn-antigen, respectively. In this work, using ASF or OSM we affinity-purified anti-T and anti-Tn antibodies from normal human plasma and tested their ability to specifically recognize tumor human tissues. Whereas purified anti-T antibodies (purity degree increase of 127-fold, and 22% recovery) were mainly IgG, for purified anti-Tn antibodies (purity degree enhancement of 125-fold, and 26% yield) the IgM fraction was predominant over the IgG one. IgG2 subclass was significantly enriched in both purified antibody samples. Purified antibodies did not bind normal human tissue (0/42), although recognized malignant tissues from different origin such as colon carcinoma (11/77 by anti-Tn; 7/79 by anti-T), breast carcinoma (10/23 by anti-Tn; 7/23 by anti-T), and kidney carcinoma (45/51 by anti-Tn; 42/51 by anti-T). Our results suggest that purified human anti-Tn and anti-T antibodies have a potential as anti-tumor therapeutic agents; restoring their levels in human sera could positively affect the evolution of patients with epithelial tumor pathologies. | |
dc.language | eng | |
dc.publisher | Nature Publishing Group | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/http://www.nature.com/articles/s41598-019-44601-9 | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1038/s41598-019-44601-9 | |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Purification process | |
dc.subject | Human antibodies | |
dc.subject | Carcinoma recognition | |
dc.subject | Protein therapy | |
dc.title | Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:ar-repo/semantics/artículo | |
dc.type | info:eu-repo/semantics/publishedVersion | |